X4 raises $27M series B

X4 Pharmaceuticals Inc. (Cambridge, Mass.) raised $27 million in a series B round led by Cormorant Asset Management. Undisclosed new and existing investors also participated.

X4’s lead candidate, X4P-001, is an oral CXC chemokine receptor type 4 (CXCR4; NPY3R) antagonist...